Cecilia Jones

Director of Finance/CFO bij AGIOS PHARMACEUTICALS, INC.

Vermogen: 433 922 $ op 31-03-2024

49 jaar

Health Technology

Consumer Services

Actieve functies van Cecilia Jones

Bedrijven	Functie	Begin	Einde
AGIOS PHARMACEUTICALS, INC.	Director of Finance/CFO	26-09-2022	-

Bedrijven	Functie	Begin	Einde
LOGICBIO THERAPEUTICS, INC.	Comptroller/Controller/Auditor	-	23-09-2022
	Director of Finance/CFO	11-01-2021	23-09-2022
	Investor Relations Contact	11-01-2021	23-09-2022
	Treasurer	-	23-09-2022
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	01-01-2003	01-11-2009
BIOGEN INC.	Corporate Officer/Principal	01-07-2015	-

Harvard Business School

Masters Business Admin

Internationaal

Verenigde Staten

Operationeel

Director of Finance/CFO	2
Corporate Officer/Principal	2
Comptroller/Controller/Auditor	1

Sectoraal

Health Technology	5
Consumer Services	2

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	2
BIOGEN INC.	Health Technology
AGIOS PHARMACEUTICALS, INC.	Health Technology

Bedrijven in privébezit	2
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Health Technology
LogicBio Therapeutics, Inc. LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA.	Health Technology

Bedrijven in privébezit

Health Technology